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The interplay between rewiring tumor metabolism and oncogenic driver mutations is only 
beginning to be appreciated. Metabolic deregulation has been described for decades as 
a bystander effect of genomic aberrations. However, for the biology of malignant cells, 
metabolic reprogramming is essential to tackle a harsh environment, including nutrient 
deprivation, reactive oxygen species production, and oxygen withdrawal. Besides the 
well-investigated glycolytic metabolism, it is emerging that several other metabolic 
fluxes are relevant for tumorigenesis in supporting redox balance, most notably pentose 
phosphate pathway, folate, and mitochondrial metabolism. The relationship between 
metabolic rewiring and mutant genes is still unclear and, therefore, we will discuss how 
metabolic needs and oncogene mutations influence each other to satisfy cancer cells’ 
demands. Mutations in oncogenes, i.e., PI3K/AKT/mTOR, RAS pathway, and MYC, and 
tumor suppressors, i.e., p53 and liver kinase B1, result in metabolic flexibility and may 
influence response to therapy. Since metabolic rewiring is shaped by oncogenic driver 
mutations, understanding how specific alterations in signaling pathways affect different 
metabolic fluxes will be instrumental for the development of novel targeted therapies. In 
the era of personalized medicine, the combination of driver mutations, metabolite levels, 
and tissue of origins will pave the way to innovative therapeutic interventions.
Keywords: metabolic reprogramming, one-carbon metabolism, OXPHOS, oncometabolites, pentose phosphate 
pathway
iNTRODUCTiON: MeTABOLiC DeReGULATiON AND TUMOR 
PROGReSSiON
Despite being considered for decades as a bystander effect of the genomic alterations that char-
acterize a cancer cell, it is now established that the deregulation of key metabolic hubs can be 
a tumorigenic driver and that several cellular signaling alterations converge toward metabolic 
Abbreviations: 1-CM, one-carbon metabolism; ALDH, aldehyde dehydrogenase 1 family member; αKG, alpha-ketoglutarate; 
DRP1, dynamin-related protein; F6P, fructose-6-phosphate; FH, fumarate hydratase; G3P, glyceraldehyde-3-phosphate; G6P, 
glucose-6-phosphate; G6PDH, glucose-6-phosphate dehydrogenase; IDH, isocitrate dehydrogenase; MDM2, mouse double 
minute 2 homolog; MOMP, mitochondrial outer membrane permeabilization; MTHFD, methylenetetrahydrofolate dehydro-
genase (NADP + dependent); NADPH, nicotinamide adenine dinucleotide phosphate; OMM, outer mitochondria membrane; 
PGAM1, phosphoglycerate mutase 1; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator-1 alpha; 
PHGDH, phosphoglycerate dehydrogenase; SDH, succinate dehydrogenase; SSP, serine synthesis pathway; TCA, tricarboxcylic 
acid; TIGAR, TP53-induced glycolysis and apoptosis regulator; PPP, pentose phosphate pathway; ROS, reactive oxygen species.
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alterations and the accumulation of specific intermediates 
endowed with oncogenic potential (1). The altered metabolic 
scenario of a cancer cell inevitably affects its cellular redox 
homeostasis. Particularly, cancer cells are characterized by 
an altered redox status and enhanced reactive oxygen spe-
cies (ROS) that have been shown to drive and sustain cancer 
cells proliferation. Higher ROS levels are compensated by an 
increase in antioxidant mechanism that allows the cancer 
cell to survive in a pro-oxidant environment. However, such 
pro-oxidant condition favors DNA damage and genomic insta-
bility, events that concur to enhance the malignant traits of 
cancer cells, including metabolic reprogramming. Metabolic 
reprogramming and redox homeostasis are intimately 
interconnected and, therefore, such a vicious loop is further 
promoted by genetic lesions that activate proto-oncogenes or 
repress onco-suppressors, leading to cancer progression (2).
This review gathers the recent findings on the role of oncogenic- 
dependent metabolic reprogramming that cancer cells undergo 
during the different stages of tumor progression. Importantly, 
the main metabolic pathways concurring to redox homeostasis 
have been reviewed with a focus on the correlation between onco-
genic lesions and ROS-dependent metabolic reprogramming.
PeNTOSe PHOSPHATe PATHwAY (PPP)
The PPP, also termed phosphogluconate pathway, diverges 
from the glycolytic pathway after the initial phosphorylation of 
glucose catalyzed by the glycolytic enzyme hexokinase. Glucose-
6-phosphate (G6P) is the principal substrate of the G6P dehy-
drogenase (G6PDH), the rate-limiting enzyme of the PPP. The 
primary endpoint of the PPP is to provide (i) phospho-pentoses, 
for the nucleotides and nucleic acids synthesis and (ii) reducing 
equivalents that are used for both reductive biosynthesis reactions 
and for redox homeostasis. Indeed, the production of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) in the 
oxidative phase of the pathway is essential for redox cellular 
homeostasis; directly, by buffering enhanced reactive oxygen 
intermediates and indirectly for the regeneration of the oxidized 
form of the glutathione (GSH), a pivotal molecule in neutral-
izing intracellular ROS levels (3). The non-oxidative phase of the 
PPP is characterized by a series of reversible reactions catalyzed 
by transaldolase (TALDO) and transketolase (TKT) enzymes 
that recruit additional glycolytic intermediates, i.e., fructose-6- 
phosphate (F6P) and glyceraldehyde-3-phosphate (G3P), to 
produce phospho-pentoses (4).
Despite leading to glucose oxidation, the main role of the 
PPP is anabolic rather than catabolic. Depending on the cellular 
requirements and response to exogenous stimuli, the PPP and 
the glycolysis cooperate to provide the needed metabolites. For 
instance, rapidly proliferating cells will boost the PPP to meet 
the requirements for pentoses to support nucleotide biosynthe-
sis, both from G6P (oxidative phase) and from F6P and G3P 
(non-oxidative phase). While this condition is representative of 
a rapidly dividing cancer cell, a cell that has to maintain the 
redox cellular balance will sustain the oxidative branch for 
NADPH production and re-direct the non-oxidative branch 
toward F6P synthesis from the phospho-pentoses, which are 
then regenerating G6P to replenish the oxidative branch. ROS 
accumulation and subsequent oxidative stress result from the 
unbalance between ROS generation (e.g., from electron trans-
port chain), and antioxidant mechanism (e.g., GSH, thioredoxin, 
and catalase) requiring NADPH to function as ROS scavengers. 
Therefore, not surprisingly, PPP deregulation has been linked to 
the pathogenesis of several diseases, such as G6PDH-deficiency. 
G6PDH-deficiency, and subsequent reduced activity, impairs 
the ability of erythrocytes to generate NADPH, hence expos-
ing the cells’ phospholipid bilayer to the detrimental effect of 
ROS, leading to hemolytic anemia. G6PDH-deficiency is not 
associated with acquired susceptibility to particular diseases 
and preventing oxidative stress-inducing situations (i.e., certain 
drugs and food) leaves G6PDH-deficiency bearing individuals 
asymptomatic. Interestingly, G6PDH-deficiency is protective 
against malaria, heart, and cerebrovascular disease (5).
However, since the focus of this review is on cancer, we 
will discuss how PPP deregulation is affected by oncogenic-
dependent metabolic reprogramming and how this impacts 
on tumor progression and therapy resistance. Interestingly, 
G6PDH-deficiency has been reported to reduce cancer sus-
ceptibility and incidence. A retrospective observational study 
in ~4,000 patients that underwent colonoscopy with a 10 years 
follow-up from Sardinia region (Italy), where G6PDH-deficiency 
prevalence ranges between 12 and 24% and is often caused by 
the G6PDHC563T variant, shows that G6PDH-deficiency is asso-
ciated with reduced colorectal cancer risk (5, 6). The potential 
explanation of such counterintuitive epidemiological data may 
be explained by the NADPH and PPP dependence that sustain 
lipid anabolism in cancer cells. Additionally, NADPH deficiency 
due to G6PDH alterations may alter the redox balance, hence 
reducing intracellular ROS levels, which play an important role 
in cancer initiation by increasing the DNA mutation rate and the 
synthesis of proinflammatory cytokines (7).
Glucose-6-phosphate dehydrogenase expression and activity 
have been proposed to be importantly influenced by genetic 
alterations that occur on oncogenes and/or oncosuppressor that 
ultimately lead to a pro-mitogenic signaling pathways activation 
of the cancer cells (Figure 1). Indeed, while the reprogramming 
of certain metabolic hubs seems to correlate with particular 
tumor phenotype and be associated with certain type of thera-
peutic option, the increased demand of NADPH, used for either 
antioxidant response and/or cellular anabolism than pentoses, is 
a prerequisite of almost any cancer (4). G6PDH is regulated by a 
plethora of extracellular stimuli, e.g., growth factors, that impacts 
on its expression and activity via the MAPK and PI3K signaling 
pathways. Since these signaling pathways are often hyper-acti-
vated in cancer due to oncogenes activation (e.g., K-RAS, MYC, 
and growth factor receptors), or oncosuppressors inactivation 
(e.g., p53 and PTEN loss-of-function and inactivation), any 
alterations that impact on these players may lead to G6PDH 
enhanced expression and activity (8, 9). Additionally, some of the 
aforementioned cancer-inducing genes can also regulate G6PDH 
function independently of the signaling cascade. For instance, 
loss of p53, which directly controls and inhibits glucose trans-
porters expression (10), leads to enhanced glucose uptake that 
can be diverted into the PPP pathway. Similarly, glucose diversion 
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FiGURe 1 | One-carbon metabolism (1-CM) and pentose phosphate pathway (PPP) at the cross-road between anabolism and redox balance. Simplified scheme  
of the crosstalk between metabolic and signaling pathways that can occur in cancer cells. Pro-tumorigenic signals are represented in red and anti-tumorigenic in 
green. Glycolysis regulates both PPP and 1-CM. Serine signaling pathway, once PKM2 activity is inhibited (red light), leads to glycolytic intermediates accumulation 
hence fueling both PPP and 1-CM. Serine metabolism enzymes bridge the shunt between glycolysis and 1-CM, with specific oncogene upregulating the enzymes 
involved [i.e., phosphoglycerate dehydrogenase (PGHDH), phosphoserine aminotransferase 1 (PSAT1), phosphoserine phosphatase (PSPH)], leading to serine 
generation and antioxidant machinery intermediates (cysteine and glutathione). Serine hydroxymethyltransferase (SHMT) mediates the conversion between serine 
and glycine with the concurrent transformation of tetrahydrofolate (THF) into 5,10-methylenetetrahydrofolate (meTHF). Aldehyde dehydrogenase 1 family member 
(ALDH1L) mediates the opposite reaction with concurrent generation of NADPH, similarly methylenetetrahydrofolate dehydrogenase (MTHDF) transform meTHF  
into 10-formyltetrahydrofolate (F-THF) with concurrent generation of nicotinamide adenine dinucleotide phosphate. The main chemotherapy agents are represented 
in blue. Dehydroepiandrosterone (DHEA), epigallocatechin gallate (EGCG), amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), 6-aminonicotinamide 
(6-AN), and 5-fluorouracil (5-FU).
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into the PPP can also be a consequence of the downregulation 
of TP53-induced glycolysis and apoptosis regulator (TIGAR), 
a p53-dependent gene known to inhibit the glycolytic enzyme 
phosphoglycerate mutase 1 (PGAM1) that leads to the increase 
of the oxidative PPP by reducing the amount of 3-phosphoglycer-
ate (3PG), which has been reported to inhibit the PPP enzyme 
6-phosphogluconate dehydrogenase (6PGDH) (11). Finally, 
p53-mediated G6PDH inhibition can also be mediated by direct 
protein-to-protein contact (3). DNA damage, telomeric instability, 
or oxidative stress can activate the ataxia telangiectasia-mutated 
(ATM) kinase, which in turn activates p53. Interestingly, ATM 
promotes the Hsp27 phosphorylation and binding to G6PDH, 
stimulating its activity and, therefore, increasing the PPP flux and 
the subsequent NADPH and phospho-pentoses production (12). 
However, others have reported that loss of p53 enhances NADPH 
production, therefore, by generating a negative feedback on the 
PPP. These reported contradictory results may be related to the 
different role that p53 can exert on either cell cycle or apoptosis 
(3). Finally, it has been recently demonstrated that polo-like 
kinase 1 (PLK1), a key player in cell mitosis, is able to directly 
phosphorylate and activate G6PDH (13).
Although G6PDH is the major rate-limiting step of the PPP, 
the amount of phosphorylated glucose trapped into the cells and 
the expression of enzymes regulating the glycolytic rate can also 
affect the PPP flux. Indeed, higher levels of G6P are required to 
sustain oxidative and non-oxidative branches of the PPP and this 
can be achieved by (i) enhancing the amount of glucose that is 
phosphorylated by the glycolytic-rate limiting enzyme hexoki-
nase 2 (HK2), the main isoform expressed by cancer cells, and (ii) 
by engulfing the glycolytic pathway and subsequent enhancing 
the accumulation of glycolytic intermediates. HK2 enhanced 
expression, known to be regulated by oncogenic RAS activation, 
is essential to sustain the non-oxidative phase of the PPP in lung 
cancer (14). Additionally, pyruvate kinase (PK)-M2, an isoform 
of the PK that converts phosphoenolpyruvate (PEP) into pyruvate 
and that is expressed by many cancers, can be controlled by post-
translational modifications (e.g., oxidation, phosphorylation, 
and acetylation) that impair the PKM2 tetrameric-mediated 
metabolic function favoring the PKM2 dimer formation (15, 16). 
Particularly, an increase in the PKM2 dimer content induces an 
accumulation of the glycolytic intermediates, including that of 
G6P, that results in increased metabolic flux into the PPP and 
enhanced NADPH production (17–20).
6-Phosphogluconate dehydrogenase, the third enzyme 
involved in PPP, that catalyzes the oxidative decarboxylation 
of 6-phosphogluconate to ribulose 5-phosphate and CO2, with 
concomitant reduction of NADP to NADPH, has also been 
reported to be upregulated in many solid cancers and has been 
often correlated to G6PDH (4).
Transketolase and TALDO are the two key enzymes in 
the non-oxidative branch and divert glycolytic intermediates 
(e.g., F6P and G3P) into the PPP to fuel ribonucleotides bio-
synthesis, essential for fast proliferating cancer cells (21). Their 
expression levels have been found deregulated in cancer cells. 
Particularly, oncogenes activation that leads to hyper-proliferation 
may also have an impact on the non-oxidative branch of the PPP, 
favoring ribonucleotides biosynthesis. Indeed, the use of isogenic 
colorectal cancer cell lines that express either the mutant or the 
wild-type form of K-RAS or B-RAF shows that the enzymes 
of the non-oxidative branch of the PPP (ribose-5-phosphate 
isomerase and TKT) are upregulated in the K-RAS-mutant cell 
lines (20). These results are in line with a previous report showing 
that K-RAS mutations in pancreatic cancers enhance the non-
oxidative branch of the PPP (22).
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Due to the important role in maintaining the redox homeo-
stasis, PPP is also importantly regulated by nuclear factor 
erythroid 2-related factor 2 (NRF2), a transcription factor that 
has an essential role in combating enhanced ROS levels and 
controlling ROS detoxification and homeostasis. NRF2, which 
is usually bound in its inactive form to the cytosolic Kelch-like 
ECH-associated protein 1 (KEAP1), is able to translocate into 
the nucleus upon NRF2-KEAP1 destabilization, oxidative stress, 
or protein succination driven by fumarate accumulation (23, 24). 
Once into the nucleus, NRF2 activates antioxidant response 
genes and this activation have been reported to play a major role 
in protecting cancer cells from the oxidative stress induced by 
antitumoral therapies. Activation of NRF2 or destabilization of 
NRF2–KEAP1 interaction caused by genetic modifications of 
NRF2 and KEAP1 has been reported in several cancer types, 
including those of liver, esophagus, intestine, lung, and breast 
(25, 26). Moreover, the increased expression of NRF2-dependent 
genes correlates with poor prognosis (27–29). NRF2 is tightly 
linked to metabolic reprogramming. In particular, NRF2 tar-
geting impairs the activity and the expression of the enzymes 
involved in the PPP (e.g., G6PDH, TKT, and 6PGDH), a pro-
cess that has been shown to be mediated by microRNAs (30). 
Recently, it has been shown that NRF2 enhances expression of 
the PPP enzymes. The consequent increase of the PPP flux leads 
to acquired proliferative advantage in the presence of constitu-
tive activation of PI3K-AKT signaling pathway due to PTEN 
deletion (31). Oncogenic activation of K-RAS and B-RAF and 
overexpression of MYC, together with enhanced activation of the 
PI3K/AKT pathway induce NRF2 nuclear translocation, further 
rein forcing the link between oncogenes activation and NRF2-
mediated PPP induction and redox homeostasis alterations.
An important driver of cancer cell growth and survival is 
the activation of the PI3K/AKT pathway that can occur as a 
consequence of external stimuli, e.g., growth factor receptor 
activation or as a consequence of a genetic lesion, e.g., via PTEN 
loss-of-function that ultimately leads to PI3K/AKT-mediated 
mTOR activation. It has been extensively reported that mTOR 
can control cell metabolism, including the glycolytic pathway 
and PPP (32). mTOR kinase can associate with different subunits 
leading to two signaling complexes, mTORC1 and mTORC2. 
Particularly, mTORC1 regulates cell proliferation and anabolism.
Indeed, it has been shown that mTORC1 activation sustains 
the metabolic flux through both glycolysis and the oxidative 
arm of PPP. Duvel and coworkers demonstrated that mTORC1 
activation promotes G6PDH expression, a process that is in part 
mediated by SREBP1 (33). Additionally, it has been recently 
reported that mTOR-dependent G6PDH expression can be 
controlled by androgen receptor signaling in prostate cancer 
models (34). In the Duvel et al. manuscript it was also reported 
that mTOR activation induces HIF-1α expression and stabiliza-
tion, leading to the transcriptional activation of a plethora of 
metabolic HIF-dependent genes in a hypoxia-independent 
mechanism (33). HIF-1α stabilization have been also reported to 
control the expression of TKT in pancreatic cancer cells, hence 
impacting on the non-oxidative branch of the PPP (35) and 
subsequent response and resistance to gemcitabine. However, 
also hypoxia has been reported to impact on PPP flux. Indeed, 
colon cancer cells subjected to 1% hypoxia increase their intra-
cellular levels of ribose-phosphates and gluconic-acid, terminal 
and intermediate compounds of the oxidative branch of PPP, 
respectively (36).
ONe-CARBON MeTABOLiSM (1-CM): THe 
SeRiNe SYNTHeSiS PATHwAY (SSP)
One-carbon (1-C) metabolism is responsible for the transfer of 
1-C unit through folate intermediates, coupling the folate and 
the methionine cycle. This pathway is required for nucleic acid 
synthesis (purine and thymidine), amino acids homeostasis 
(methionine, serine, and glycine), antioxidant defense (NADPH 
production) and epigenetic maintenance (homocysteine 
re-methylation) (37–39). In particular, the methionine cycle 
produces the substrate for the S-adenosyl methionine (SAM)-
dependent methyl transferases. These enzymes are responsible 
for the addition of methyl groups to proteins, lipids, secondary 
metabolites, and nucleic acids and are, therefore, essential for 
epigenetic modifications.
In order to sustain the NADPH-mediated antioxidant defense, 
1-CM supplements the major source of intracellular NADPH, 
which is produced by the oxidative branch of the PPP and by the 
malic enzyme. In the 1-C cycle, there are two steps that can lead 
to NADPH production: one catalyzed by the methyl dehydroge-
nases, mitochondrial 2-like (MTHFD2L) and cytosol MTHFD1, 
and the other catalyzed by the formyl dehydrogenases, cytosolic 
aldehyde dehydrogenase 1 family member L1 (ALDH1L1) and 
mitochondrial aldehyde dehydrogenase 1 family member L2 
(ALDH1L2).
1-C units are mainly derived from serine, formate, and 
histidine, which are directly used in the cytosolic folate cycle or 
by glycine, sarcosine, and dimethylglycine, which are converted 
into folate and secreted into the cytosol (40, 41). Glycine has 
a prominent role because it can contribute to both the folate 
cycle and to serine production. In particular, the folate cycle is 
completed in the cytosol by serine hydroxymethyltransferase 
2 (SHMT2), which catalyzes the concomitant conversion of 
l-serine to glycine and tetrahydrofolate to 5,10-methyleneTHF. 
Hence, glycine represents a precursor of glutathione and purines, 
required for antioxidant defense and proliferation, respectively. 
If necessary, glycine can be converted into serine with the con-
comitant production of 5,10-methylene-THF, although some 
of the specificity of serine-related metabolic functions are lost 
and this results, for instance, in decreased purine synthesis and 
reduced cell proliferation (42, 43).
The main donor of 1-C to the folate cycle is the non-essential 
amino acid serine that can be synthetized de novo by the cell (41), 
a process that requires three MYC-regulated enzymes, PHGDH, 
PSAT1, and PSPH. The backbone of serine is derived from the 
glycolytic or gluconeogenic pathway, with the production of 
the intermediate 3PG. The main transcriptional activator of the 
three SSP enzymes is ATF4, a cAMP-response element-mediated 
transcription factor that mediates oxidative stress response 
(via NRF2) (44), serine starvation (via mouse double minute 2 
homolog MDM2) (45), and histone methylation (41).
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At physiological levels, serine can act as an allosteric activa-
tor of the metabolic activity of PKM2, which catalyzes the last 
step of glycolysis, preventing the redirection of 3PG into serine 
synthesis and promoting glycolysis. Similarly, AKT-mediated 
phosphorylation of MDM2, a negative regulator of p53, on Ser166 
induces the association of MDM2 to PKM2, in order to promote 
PKM2 activity. In condition of oxidative stress, serine depriva-
tion, and the consequent decrease in the allosteric activation 
of PKM2, the non-phosphorylated form of MDM2 is recruited 
to the chromatin with ATF4, which activates a transcriptional 
program involved in amino acid metabolism and redox homeo-
stasis (45–48). In particular, during oxidative stress, ATF4 has 
been reported to be transcriptionally activated by NRF2, which 
induces the transcription of SSP-related genes and regulates the 
antioxidant response (44). While during serine starvation, the 
inhibition of PKM2 metabolic activity leads to the accumulation 
of glycolytic intermediates that results in de novo serine synthesis 
activation, if G3P is used as a substrate for the PHGDH, or into 
oxidative PPP activation and/or if G6P is used as a substrate for 
G6PDH, as described above (27).
mTORC1 signaling, through ATF4, activates the transcrip-
tion of MTHFD2 in both normal and cancer cells, increasing 
de novo purine synthesis necessary for nucleic acid production 
(48). PKM2-expressing cells can maintain mTORC1 activity and 
pro liferate in serine-depleted medium (49).
It has been reported that highly proliferative cells require an 
exogenous amount of serine supply for their optimal growth to 
adjunct the de novo synthesis (50). Indeed, additional serine 
sources are derived from diet intake, from breakdown of intra-
cellular proteins, and from the conversion of glycine. In serine 
starve condition, P53 null cells have an impaired proliferation 
rate and tumor growth is reduced in mice fed with serine-free 
diet (50).
Due to its role in maintaining amino acid and redox homeo-
stasis and epigenetic regulation, it is not surprising that the SSP 
has been found altered in cancer. Since serine can become a 
limiting factor, cancer cells can adopt two strategies to bypass 
this issue: they can increase de novo serine synthesis to become 
dependent on some alternative amino acids, such as glutamine, 
or can promote exogenous serine intake (41). For instance, 
PHGDH is commonly altered in cancer cells, either upon gene 
amplification (51, 52), or activation of transcription factors 
promoting expression of SSP enzymes, e.g., MYC and NFR2 
(44). Among the signaling pathways that promote the 1-C 
metabolism, it has been reported that HER2 amplification (53) 
increases the expression of PHGDH (Figure 1). The PHGDH 
promoter is positively regulated by specificity protein 1 (SP1) 
and nuclear transcription factor Y (NFY), two transcription 
factors that are often upregulated in cancer (54). PHGDH is 
overexpressed and associated with poor prognosis in triple 
negative breast cancer and melanoma (44, 52, 55). While 
genomic alterations are typical of PHGDH, the high expres-
sion of the folate enzyme is due to aberrant transcriptional 
regulation. In non-small cell lung cancer (NSCLC), ATF4 
overexpression can be caused by KEAP1-mediated activation 
of NRF2 (44) or activation of the PI3K/mTOR signaling path-
way (48, 56, 57).
Under hypoxia, HIF-1α and MYC can mediate SHMT2 
increased levels that correlate with poor prognosis. Among the 
enzymes that catalyze the reactions coupled with the production 
of NADPH, THF dehydrogenases (cytosolic ALDH1L1 and 
mitochondrial ALDH1L2) and MTHF-dehydrogenases (mito-
chondria MTHFD2L and cytosolic MTHFD1) are involved in 
cancer. ALDH1L1 is usually underexpressed in cancer cells (57), 
as its overexpression would deplete the cytosolic 10-formyl-THF 
used for the synthesis of nucleotides. Conversely, ALDH1L2 is 
overexpressed to control mitochondrial redox homeostasis under 
hypoxia and to support melanoma cells metastatization (56). 
K-RAS activating mutation is associated with the high expression 
of the folate metabolism enzyme, MTHFD2 (47), and this leads 
to increased nucleotide synthesis, increased ATP and NADH 
production, and finally to enhanced mitochondrial NADPH 
production which is essential for struggling ROS increased levels. 
Conversely, during nutrient deprivation or hypoxia, when intra-
cellular levels of ATP decline, 5′ AMP activated kinase (AMPK) 
activation represses the expression of MTHFD2 (50, 58).
MiTOCHONDRiAL MeTABOLiSM
Reactive oxygen species mtROS are generated by mitochondria 
as a natural by-product of electron transport chain activity. 
Recently, it has been reported that mitochondria ROS (mtROS) 
can activate tumorigenic signaling and metabolic reprogram-
ming. Increased production of ROS has long been observed to be 
a hallmark of many tumors and cancer cell lines. Consequently, 
this oncogenic signaling increases the expression of antioxidant 
proteins to balance the high production of ROS to maintain 
redox homeostasis.
Indeed, several aspects of mitochondrial biology, including 
biogenesis and turnover, fission and fusion, and mitochondria-
controlled metabolic signaling are controlling cellular transfor-
mation (59, 60).
Mitochondria are signaling hubs and bioenergetics organelles, 
which play an important role in cellular adaptation to environ-
mental changes, directly responding to nutrient availability. For 
instance, during stress condition, such as extracellular acidosis 
or hypoxia (60, 61), mitochondria tune their metabolism to 
support fatty acid synthesis by upregulating the reductive 
carboxylation of α-ketoglutarate via citrate generation to sup-
port both production of lipid membranes and production of 
intermediates for protein acetylation (13).
An element controlling mitochondrial function is the mito-
chondrial mass, which can vary greatly in cell, depending on the 
microenvironmental context and oxidative fuels availability of cer-
tain nutrients. The mitochondrial mass is regulated by biogenesis 
and turnover, two different pathways that can act as positive and 
negative regulators of tumorigenesis (59). It is generally accepted 
that MYC is one of the key activator of mitochondrial biogenesis 
in cancer, and opposed effects are exerted by the activation of 
HIF-1α signaling pathway (62), as well as FOXO3a (62–64). In 
physiological conditions, MYC couples mitochondrial biogen-
esis with cell-cycle progression, whereas once deregulated in 
cancer it stimulates mitochondrial metabolism to support rapid 
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cell growth (63). The major impact of MYC on mitochondria 
function depends on the direct regulation of the transcriptional 
coactivator peroxisome proliferator-activated receptor gamma 
coactivator-1 alpha (PPARGC1A, best known as PGC-1α) (58), 
that is responsible for the enhanced metabolic plasticity of aggres-
sive cancer cells. In particular, PGC-1α levels have a dichotomous 
effect on tumors, with an upregulation that has been associated 
with pro- or anti-tumorigenic effects on the basis of tumor types 
and experimental conditions (65–67).
The discovery of the tumor suppressor liver kinase B1 
(LKB1) and its major downstream effectors PGC-1α and 
AMPK established a central metabolic hub at the crossroad 
between energy regulation and cancer development (68). It 
has been already reported that LKB1 plays an important role 
in reducing intracellular ROS in response to oxidative stress 
(69, 70). Consequently, LKB1 loss increases oxidative DNA 
damage and mutations induced by the accumulation of ROS. 
In NSCLC, the redox imbalance caused by LKB1 inactivation 
modulates tumor plasticity and promotes tumor progression 
via metabolic adaptation (71).
In addition to aerobic glycolysis, cancer cells often rely on 
elevated glutaminolysis, supporting mitochondrial metabo-
lism for cancer growth. In order to fuel the tricarboxcylic acid 
(TCA) cycle, glutamine is first converted to glutamate by glu-
taminase and then to α-ketoglutarate by glutamate dehydro-
genase or aminotransferases. Therefore, glutamine supports 
the high proliferating rate of cancer cells by acting as substrate 
for the TCA cycle to produce building blocks, including ATP, 
lipids, nucleotides, and proteins. MYC oncogene transcription-
ally promotes glutaminolysis and the use of glutamine as a 
bioenergetic substrate (72). The final effect of MYC-dependent 
glutaminolysis is a profound mitochondrial metabolism repro-
gramming due to glutamine catabolism dependency and TCA 
cycle anaplerosis. Noteworthy, reductive carboxylation under 
hypoxia has been shown to promote generation of 2-hydroxy-
glutarate (2HG) even in absence of isocitrate dehydrogenase 
(IDH) mutations (73, 74).
Recently, it has been reported that an association with the 
oncometabolite 2HG accumulations and MYC pathway activation 
in breast cancer patients (75). This analysis identified a subtype 
of tumors characterized by higher levels of 2HG that associate 
with poor prognosis and with a distinct DNA methylation pat-
tern. These tumors tend to overexpress glutaminase, suggesting 
a functional relationship between MYC activation and glutamine 
dependence in breast cancer (75, 76).
2-Hydroxyglutarate is a TCA byproduct that can be gener-
ated in certain conditions and has been termed oncometabolite, 
since its production can drive oncogenesis (77). To date, various 
germline and somatic mutations in mitochondrial enzymes 
led to oncometabolites accumulation. For instance, succinate 
dehydrogenase (SDH), fumarate hydratase, and IDH (78) once 
mutated lead to cellular transformation and oncogenesis (79) via 
augmented levels of fumarate, succinate, and 2HG, respectively 
(79). Those molecules present various activity, altering epigenetic 
pattern, enzymatic activity, or the aforementioned protein succi-
nation induced by fumarate. Coherently with the oncogenic role 
of such metabolite, TRAP1 expression has been shown to induce 
cellular transformation by inhibiting SDH, thus promoting suc-
cinate build-up (80, 81).
Recently, Morita et al. reported a key role for mTORC1 signal-
ing, stimulating mitochondrial biogenesis and activity, bolstering 
ATP production capacity (82). This effect is mediated by the activ-
ity of 4E-BP proteins that mediate mTORC1-driven translation 
of mitochondria-related mRNAs, mitochondrial respiration and 
biogenesis, and ATP production. These data reveal a feed-forward 
mechanism by which translation impacts mitochondrial function 
to maintain cellular energy homeostasis (82). Consistently, in 
muose Embryonic Stem cells  has been shown that tumorigenicity 
and teratoma formation was bound to increased mitochondrial 
metabolism linked to higher mTOR activity (83).
Mitochondria are extremely dynamic structures and the bal-
ance of fission and fusion is responsible for their morphology 
(84). The mitochondrial division is controlled by dynamin-
related protein 1 (Drp1), a GTPase that is recruited to the outer 
mitochondria membrane. Drp1 mitochondrial translocation 
is regulated by different kinases that are activated by specific 
cell-cycle and stress conditions. Several studies described that 
cancer cells have an imbalance fission-fusion state, character-
ized by high fission and decreased fusion activities, causing a 
fragmentation of mitochondrial network (85). Disruption of 
mitochondrial dynamics are one of the key features of K-RAS-
induced cellular transformation, by stimulating mitochon drial 
fragmentation via ERK1/2-mediated phosphorylation of 
Drp1 (86). In addition, the mitochondrial remodeling caused 
by oncogenic K-RAS directly increases ROS generation and 
impacts the mitochondrial function itself (87). Similarly to 
what has been reported for the MYC oncogenic activation, the 
mitochondrial network remodeling caused by oncogenic K-RAS 
generates general tumorigenic stimuli that promote transfor-
mation. However, further studies are needed to understand 
the effects of oncogenic signaling pathways on mitochondrial 
dynamics. K-RAS-mediated metabolic remodeling drives also 
an augmented glutamine metabolism and malic enzyme activ-
ity, acting as an important source of NADPH (Figure 2) (88). 
Mitochondrial remodeling is also altered by ATPase inhibitory 
factor 1 (ATPIF), a factor exerting pro-tumorigenic function by 
preventing cristae remodeling and mitochondrial depolariza-
tion by inhibiting ATPase activity of complex V (89).
Redox homeostasis is an important process that can fuel 
anchorage-independent growth. In this stressful condition, 
mitochondrial IDH2 supports NADPH pool to decrease mtROS 
accumulation (41). Consequently, the limitation of excessive 
generation of mtROS is a converging pattern that can support 
metastasis formation, although a moderate degree of mtROS 
directly promotes metastasis formation (56, 90). Accordingly, 
inhibiting mitophagy by BNip3, hence degradation of dysfunc-
tional mitochondria, promotes mtROS generation sufficient to 
induce metastasis in breast cancer (91).
Another important player in the regulation of mitochondrial 
metabolism and intracellular redox homeostasis is p53, a key 
regulator of several biological processes, including energy 
homeostasis, apoptosis, and cell-cycle arrest, through transcrip-
tion-dependent and -independent mechanisms (92). To regulate 
energy metabolism, p53 represses glycolysis, by regulating the 
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expression of TIGAR, PGAM1, and PDK2 (pyruvate dehydroge-
nase kinase 2), and promotes oxidative phosphorylation process.
Beside on its nuclear role for gene expression, a transcription-
independent role of p53 in inducing mitochondrial apoptosis 
has been suggested (93). The mitochondrial regulation of p53 is 
critical for the control of the cellular switch between survival and 
apopotosis. In fact, several studies have shown that after DNA 
damage, p53 is translocated to mitochondrial outer membrane, 
causing mitochondrial outer membrane permeabilization 
(MOMP), caspase-3 activation, and cytochrome c release (94).
Altogether these studies demonstrate that mitochondria are 
crucial players of tumorigenesis, given that this process requires 
the ability to adapt to cellular and environmental alterations. 
Therefore, a deep understanding of molecular mechanisms regu-
lating the function of mitochondria will be critical for the next 
generation of anti-cancer agents.
TARGeTiNG ONCOGeNe-DePeNDeNT 
MeTABOLiSM: THeRAPeUTiC 
OPPORTUNiTieS
One of the biggest challenges in cancer management is to ensure 
a tailored therapeutic approach to the patients that will lead to 
the administration to the right drug (as either monotherapy or 
combination), at the right patient in the right moment. Target 
therapies have expanded the portfolio of therapeutic opportu-
nities and are often used either alone or as adjuvant therapies 
with chemotherapeutic agents. Cancer patients are usually 
matched to targeted therapies depending on driver mutations 
profiled in their tumors. However, the metabolic landscape of 
the tumor profoundly affects the response to therapy (95) and 
should be considered for optimal therapeutic intervention. 
Additionally, independently of the oncogenic drivers that 
sustain cancer growth and progression, understanding the 
metabolic network and the requirements of a given cancer, 
will offer a series of additional potential targets that could be 
exploited therapeutically.
For instance, since the PPP plays a key role in ribonucleo-
tides biosynthesis, necessary for duplicating tumor cells, and 
redox homeostasis, essential to handle the oxidative stress 
induced by anti-tumoral therapies, targeting key step of the 
PPP has been proposed as a potential therapeutic opportunity. 
However, few inhibitors targeting PPP enzymes are available 
and no clinical trials have been designed to investigate PPP 
targeting in solid cancers. However, in the preclinical setting 
PPP targeting has been effective. Due to the rate-limiting role 
of the G6PDH enzyme, its targeting has been proposed and a 
series of compounds able to inhibit its activity in vitro and/or 
in vivo have been reported. Among them, the best character-
ized is the adrenal hormone dehydroepiandrosterone (DHEA), 
shown to be effective in inhibiting proliferation and survival 
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of different cancer models (96, 97). To date, 60 trials are (or 
have been) investigating the application of DHEA in different 
cancer types (clinicaltrials.gov). However, the majority of the 
studies have evaluated DHEA for its hormonal effect rather 
than for its ability to target PPP. In the concluded trials, DHEA 
is overall well tolerated and further studies should be designed 
to draw any conclusion on its anti-metabolic effect; accord-
ingly, patients should be subgrouped based on their metabolic 
dependency, with a particular focus on G6PDH expression. 
Other compounds have been reported to target G6PDH, 
such as epigallocatechin gallate (78), chelerythrine (initially 
a PKC inhibitor), Amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo[3,4-d]pyrimidine (PP2) (98), and the Bay 11–7082 
(99) but these compounds will require additional characteriza-
tion in relevant cancer models prior to enter into the clinical 
setting. Interestingly, other compounds have been investigated 
in high-throughput screening leading to additional promising 
G6PDH inhibitors (100). The PPP can also be blocked by the 
6-aminonicotinamide (6-AN) that promotes the biosynthesis 
of the 6-AN adenine dinucleotide phosphate which is able 
to inhibit the 6PGDH enzyme, hence reducing the NADPH 
production (4). In summary, targeting the PPP pathway may 
be a successful approach because, in addition to the reduction 
of the ribonucleotide biosynthesis that ultimately impacts on 
cell division, it could potentiate the effect of other therapies 
by reducing the resistance to the oxidative stress induced by 
anti-cancer compounds.
Importantly, for an emerging group of therapies, Mayers 
and colleagues have proposed that the metabolism of a target 
tumor may be a key determinant of its response and may be 
determined by the tumor’s tissue of origin and not exclusively by 
their mutation status [see the Perspective by Vousden and Yang 
(101)]. Indeed, branched-chain amino acids (BCAAs) destiny 
has been traced in lung and pancreatic cancer mouse models 
driven by the same mutations. Lung tumors showed increased 
BCAA nitrogen uptake and utilization for the biosynthesis of 
amino acid and nucleotides, while pancreatic tumors displayed 
decreased uptake of free BCAAs (102). These differences dem-
onstrate that the tissue of origin shapes tumor metabolism and 
should be taken into account to ensure the optimal therapeutic 
approach.
It is established that p53 loss is a frequent aberration in 
many cancer cells and that one of the pro-tumoral effects 
of such genetic lesion is the increased serine dependency, 
indicating that limiting cellular serine availability may be a 
therapeutic option. Tumors with amplified SSP genes are 
only partially dependent on exogenous serine depletion and 
a potential therapeutic approach for this subset of cancer 
may come from impairing the de novo serine synthesis. For 
example, PHGDH inhibitors (21, 51, 103) could be useful 
in patients with PHGDH-amplified tumors (21, 51). Indeed, 
chemotherapy based on the inhibition of the folate metabolism 
and thymidylate synthesis has been the pioneer anti-cancer 
drugs that entered into the clinical management of cancer 
patients (104). For instance, methotrexate and 5-fluorouracil 
are still used in leukemias treatment, while pemetrexed, which 
acts by mimicking the folic acid and inhibiting the purines 
and pyrimidines biosynthesis, is administered to patients with 
mesothelioma and lung cancer (105, 106). Combination of a 
serine-free diet with metformin, an anti-diabetic biguanide 
that has been reported to target complex I of the electron 
transport chain among other targets, shows a synergistic 
antineoplastic effect (107). Side effects due to the inhibition 
of 1-CM in non-transformed cells mainly affect proliferating 
tissues, such as the intestinal epithelium and bone marrow, 
resulting in gastric damage, anemia, and immune deficiency. 
Circulating and intratumoral levels of serine and/or the 
expression of genes of the folate metabolism could be used as 
potential predictive biomarkers to identify subsets of cancers 
more likely to respond to anti-folate therapy (47, 108).
Mitochondria are gatekeepers of cell death and could, there-
fore, be considered as valuable targets for novel therapeutic 
avenues. The characteristic redox state of malignant cells, due 
to the altered electrochemical gradient across the inner mito-
chondrial membrane, renders mitochondria optimal target as 
shown by Leanza and coworkers (109). Metformin, as described 
above, has been recently proposed to be repurposed for cancer 
treatment in light of its activity as mitochondrial complex I 
inhibitor, promoting cancer specific cell death in a plethora 
of conditions, most notably in cancer stem cells (110, 111). 
In cancer tissues, the maintenance of mitochondrial structural 
integrity is essential to produce energy and overcome cellular 
stress, including nutrient deprivation and chemotherapy (112). 
Coherently, major efforts are ongoing for the development of 
novel molecules targeting directly targeting mitochondria in 
cancer (i.e., mitoCANS) (113).
CONCLUDiNG ReMARKS
Genomic aberrations play a major role in tumor development 
and targeting oncogenic drivers have been successful in many 
types of cancers. However, the advantages of the oncogenic 
activation in terms of enhancing proliferation and survival 
capacity, metastatic abilities and resistance to therapies have 
a profound effect on the metabolic network of a cancer. It is 
conceivable that, to prolong the efficacy of the current anti-
tumoral therapeutic regimens or to combat the development 
of therapy resistance, a potential successful approach could be 
the targeting of the “engine” of the tumor growth, i.e., targeting 
its driving metabolism. Indeed, independently of the drivers 
that promote tumor progression and/or therapy resistance, 
metabolic reprogramming will occur, a process that has been 
proposed to converge according to the tissue of origin more 
than of the oncogenic drivers (114). Here, we have listed a series 
of metabolic pathways that are controlled by key oncogenes 
and oncosuppressors that are often deregulated in cancer and 
could be potentially targeted. The concomitant targeting of the 
drivers together with the engine (that sustain cancer growth 
and progression) will render the signaling and metabolic 
reprogramming more difficult to occur and could represent a 
valid therapeutic approach. Further preclinical investigations 
on synthetic lethality approach in different tumor types and 
on the potential side effects that such stringent combina-
tory approach could have on normal cells are required and, 
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